| Literature DB >> 18320020 |
M P Sathisha1, V K Revankar, K S R Pai.
Abstract
The synthesis, structure, electrochemistry, and biological studies of Co(II), Ni(II), Cu(II), and Zn(II) complexes of thiocarbohydrazone ligand are described. The ligand is synthesized starting from thiocarbohydrazide and isatin. It is evident from the IR data that in all the complexes, only one part of the ligand is coordinated to the metal ion resulting mononuclear complexes. The ligand coordinates essentially through the carbonyl oxygen of the isatin fragment, the nitrogen atom of the azomethine group, and sulfur atom after deprotonation to give five membered rings. H1 NMR spectrum of the ligand shows only one set of signals for the aromatic protons, while the NH of isatin and NH of hydrazone give rise to two different singlets in the 11-14 ppm range. The formulations, [Cu(L)Cl].2H2O, [Cu(L)(CH3COO)].2H2O, [Ni(L)Cl], [Ni(L)(CH3COO)], [Co(L2)], and [Zn(L2)].2H2O are in accordance with elemental analyses, physical, and spectroscopic measurements. The complexes are soluble in organic solvents. Molar conductance values in DMF indicate the nonelectrolytic nature of the complexes. Copper complex displays quasireversible cyclic voltametric responses with Ep near -0.659 v and 0.504 v Vs Ag/AgCl at the scan rate of 0.1 V/s. Copper(II) complexes show a single line EPR signals. For the observed magnetic moment and electronic spectral data possible explanation has been discussed. From all the available data, the probable structures for the complexes have been proposed. The compounds synthesized in present study have shown promising cytotoxic activity when screened using the in vitro method and at the same time were shown to have good activity when tested using the Ehrlich ascites carcinoma (EAC) model. The antimicrobial screening showed that the cobalt complex possesses enhanced antimicrobial activity towards fungi.Entities:
Year: 2008 PMID: 18320020 PMCID: PMC2259242 DOI: 10.1155/2008/362105
Source DB: PubMed Journal: Met Based Drugs ISSN: 0793-0291
Figure 1Representative structure of the ligand.
Scheme 1Synthesis of ligand.
Scheme 2Representative synthesis of copper chloride complex.
Antimicrobial screening data of ligands and their complexes.
| Compound | Representation zone of inhibition | ||
|---|---|---|---|
| Antibacterial | Antifungal | ||
| B.c | A.n | C.a | |
| ligand | + | ++ | ++ |
|
| ++ | ++ | ++ |
|
| + | ++ | ++ |
|
|
| +++ | ++ |
|
| ++ | ++ | ++ |
|
| ++ | +++ | +++ |
|
| + | ++ | ++ |
Bacillus Cirroflagellosus = B.c.
Aspergillus niger = A.n.
Candida albican = C.a.
10 mm = − (inactive).
10–20 mm = + (weakly active).
21–25 mm = ++ (moderatively active).
26–35 mm = +++ (highly active).
36–40 mm = ++++ (most active).
DMF = 12 mm.
Norfloxacin = 29 P.a and 31 B.c;
Grisofulvin = 20 A.n and 23 C.a.
Index
(1) Concentration of the compound: 1 mg/ml in dimethyl formamide.
(2) Quantity in each cup: 0.1 ml.
(3) Diameter of the cup: 10 mm.
(4) Control of the antibacterial activity: Norfloxaicn.
(5) Control of the antifungal activity: Grisofulvin.
(6) Solvent used: Dimethyl formamide.
Elemental analysis, molar conductance, and magnetic moment measurements.
| Compounds | Found (Calc.) % | Molar conductance | Magnetic moment BM | ||||
|---|---|---|---|---|---|---|---|
| C | H | N | M | CI |
| ||
| Ligand | 55.8(56.1) | 2.8(3.2) | 23.0(23.1) | — | — | — | — |
|
| 50.9(51.1) | 2.8(2.2) | 21.4(20.7) | 7.2(7.5) | — | 2.1 | 4.98 |
|
| 43.5(44.7) | 2.0(2.4) | 17.9(18.4) | 12.2(12.8) | 7.3(7.7) | 3.5 | 3.55 |
|
| 40.3(41.8) | 2.3(2.8) | 15.7(16.2) | 10.9(11.4) | — | 2.6 | 2.92 |
|
| 39.6(40.8) | 2.3(2.8) | 16.1(16.8) | 11.9(12.7) | 6.7(7.1) | 2.2 | 1.91 |
|
| 43.1(43.6) | 2.9(3.4) | 15.9(16.1) | 11.8(12.2) | — | 2.8 | 1.89 |
|
| 46.8(47.2) | 1.9(2.5) | 18.6(19.4) | 7.1(7.5) | — | 0.7 | — |
Brine shrimp bioassay results of compounds.
| SL. no | Compound | Percentage deaths at 24 hr | LC50 mg/ml | ||
|---|---|---|---|---|---|
| 5 mg/ml | 10 mg/ml | 20 mg/ml | |||
| 1 |
| 40 | 72 | 100 | 6.17 |
| 2 |
| 27.27 | 66.66 | 100 | 7.26 |
| 3 | Ligand | 9.1 | 25 | 90 | 11.83 |
Short-term in vitro cytotoxicity of compounds towards EAC cells.
| Compounds | Percentage cell-death at different concentrations after 3 hours | LC50
| ||||
|---|---|---|---|---|---|---|
| 1 | 5 | 10 | 25 | 50 | ||
| Cisplatin | 20 | 32 | 44 | 88 | 98 | 6.6377 |
|
| 19 | 37 | 46 | 67 | 79 | 11.1475 |
|
| 16 | 31 | 43 | 65 | 82 | 10.9732 |
| Ligand | 12 | 28 | 40 | 56 | 64 | 19.1815 |
Effect of drugs on body weight changes in tumor-induced mice.
| Group | Dose (mg/Kg) i.p. | % increase in weight as compared to Day-0 (mean ± SE) | ||||
|---|---|---|---|---|---|---|
| Day-3 | Day-6 | Day-9 | Day-12 | Day-15 | ||
| Control | — |
|
|
|
|
|
| Cisplatin | 3.5 |
|
|
|
|
|
|
| 50 |
|
|
|
|
|
|
| 50 |
|
|
|
|
|
| Ligand | 50 |
|
|
|
|
|
versus Control.
Comparative effects of treatments versus cisplatin on reduction of body weights in tumor-induced mice.
| Group | Dose (mg/kg) i.p. | % Decrease in weight as compared to respective control (Mean ± SE) | |
|---|---|---|---|
| Day 12 (Mean ± SE) | Day 15 (Mean ± SE) | ||
| Cisplatin | 3.5 |
|
|
|
| 50 |
|
|
|
| 50 |
|
|
| Ligand | 50 |
|
|
Effect of drugs on the survival time in tumor-induced mice.
| Group | Dose (mg/kg) | Median survival time (days) | Mean survival time (days) | ||||
|---|---|---|---|---|---|---|---|
| MST | %T/C | %ILS | (Mean ± SEM) | %T/C | %ILS | ||
| Control | — | 18.00 | — | — |
| — | — |
| Cisplatin | 3.5 | 34.50 | 191.67 | 91.67 |
| 187.28 | 87.28 |
|
| 50 | 26.00 | 144.44 | 44.44 |
| 142.77 | 42.77 |
|
| 50 | 25.00 | 138.88 | 38.88 |
| 134.59 | 34.59 |
| Ligand | 50 | 23.00 | 127.77 | 27.77 |
| 125.48 | 25.48 |
versus control groups, MST = Median Survival Time.
Effect of the compounds on hematological parameters.
| Group | Dose | RBC | Hb | WBC | Differential Leucocyte Count % | ||
|---|---|---|---|---|---|---|---|
| (mg/kg) | (Mean ± SE) | (Mean ± SE) | (Mean ± SE) | ||||
| (Millions/mm3) | (g%) | (103cells/ mm3) | Lymphocytes | Neutrophils | Monocytes | ||
| Normal | — |
|
|
|
|
|
|
| Control | — |
|
|
|
|
|
|
| Cisplatin | 3.5 |
|
|
|
|
|
|
|
| 50 |
|
|
|
|
|
|
|
| 50 |
|
|
|
|
|
|
| Ligand | 50 |
|
|
|
|
|
|
versus normal.
versus control mice.
versus cisplatin.
Figure 3Proposed structures of the complexes.